Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Background:
Traumatic brain injury (TBI) is the world leading cause of disability in children (Winslade, 1998), causing deficits in motor function, neurocognition and adaptive behaviour (Anderson, 2001). Literature shows that age at injury is inversely related to the magnitude of deficits following TBI, highlighting the vulnerability of children for the effects of TBI.
The neurocognitive consequences of paediatric TBI have primarily been characterized by impairments in speed of information processing, attentional functioning and learning (Babikian \& Asarnow, 2009; Catroppa \& Anderson, 2...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • TBI patients will be included if they
- • have parental written informed consent
- • provide written informed consent if aged over 11 years
- • are Dutch speaking
- • have a clinical diagnosis of TBI (closed head injury)
- • have a time post-injury that is longer than 1 month
- • are aged between 6-12 years.
- Trauma control patients will be included if they:
- • have parental written informed consent
- • provide written consent if aged over 11 years
- • are Dutch speaking
- • have suffered an orthopaedic injury
- • have no history of TBI
- • and are aged between 6-12 years.
About Marsh Königs
Marsh Königs is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a strong emphasis on patient safety and data integrity, the organization collaborates with a diverse range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers, to facilitate the development of groundbreaking therapies. Marsh Königs leverages its extensive expertise in clinical trial design and management to streamline processes, ensuring adherence to regulatory standards while fostering a culture of collaboration and transparency. Committed to enhancing health outcomes globally, Marsh Königs plays a pivotal role in bringing novel treatments from concept to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, Zuid Holland, Netherlands
Eindhoven Tilburg, Brabant, Netherlands
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Huizen, Noord Holland, Netherlands
Rotterdam, Zuid Holland, Netherlands
Patients applied
Trial Officials
Jaap Oosterlaan, PhD
Principal Investigator
VU University of Amsterdam
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials